A single-center experience with inflammatory breast cancer, 1985-2003

Rory L. Smoot, Cody A. Koch, Amy C Degnim, Sylvester Sterioff, John H. Donohue, Clive S. Grant, Sunni A. Barnes, Rachel E. Gullerud, Timothy James Hobday, David R. Farley

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Hypothesis: "Up-front" surgery improves survival in inflammatory breast cancer (IBC). Design: Retrospective cohort, 1985-2003. Setting: Tertiary referral center. Patients: Consecutive patients with a primary occurrence of IBC. Main Outcome Measures: All-cause and disease-free survival. Results: One-hundred fifty-six patients were identified with IBC; 28 patients with metastatic disease were excluded from further analysis. The mean age of the remaining 128 patients was 53 years; 57% of women were postmenopausal. One hundred twenty-two patients had clinically apparent IBC. Tumors were palpable in 83 patients (mean diameter, 9.1 cm). Neoadjuvant chemotherapy was the initial therapy in 106 patients, while surgery was the initial therapy in 22 patients. The overall median survival was 37 months, with a median disease-free interval of 23 months. The 5-year survival was 42%, with a disease-free survival of 21%. Univariate analysis of recurrence identified previous hormone therapy (relative risk [RR], 0.50; P=.03), menopause (RR, 0.55; P=.01), and palpable adenopathy (RR, 1.57; P=.04) as significant factors. Univariate survival analysis highlighted previous hormone therapy (RR, 0.48; P=.04), radiotherapy (RR, 0.39; P=.02), sequence of therapy (P=.001), family history (RR, 0.47; P=.01), and palpable adenopathy (RR, 2.22; P<.001) as being important. Multivariate analysis of recurrence identified menopausal status as the key factor. Adenopathy at the initial examination was associated with decreased length of survival, while radiotherapy was associated with better survival. Conclusions: Survival from IBC remains poor. Although adenopathy and radiotherapy affected survival by multivariate analysis, the sequence of therapy was not associated with improved outcome.

Original languageEnglish (US)
Pages (from-to)567-572
Number of pages6
JournalArchives of Surgery
Volume141
Issue number6
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Inflammatory Breast Neoplasms
Survival
Radiotherapy
Survival Analysis
Disease-Free Survival
Therapeutics
Multivariate Analysis
Hormones
Recurrence
Menopause
Tertiary Care Centers
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Surgery

Cite this

Smoot, R. L., Koch, C. A., Degnim, A. C., Sterioff, S., Donohue, J. H., Grant, C. S., ... Farley, D. R. (2006). A single-center experience with inflammatory breast cancer, 1985-2003. Archives of Surgery, 141(6), 567-572. https://doi.org/10.1001/archsurg.141.6.567

A single-center experience with inflammatory breast cancer, 1985-2003. / Smoot, Rory L.; Koch, Cody A.; Degnim, Amy C; Sterioff, Sylvester; Donohue, John H.; Grant, Clive S.; Barnes, Sunni A.; Gullerud, Rachel E.; Hobday, Timothy James; Farley, David R.

In: Archives of Surgery, Vol. 141, No. 6, 2006, p. 567-572.

Research output: Contribution to journalArticle

Smoot, RL, Koch, CA, Degnim, AC, Sterioff, S, Donohue, JH, Grant, CS, Barnes, SA, Gullerud, RE, Hobday, TJ & Farley, DR 2006, 'A single-center experience with inflammatory breast cancer, 1985-2003', Archives of Surgery, vol. 141, no. 6, pp. 567-572. https://doi.org/10.1001/archsurg.141.6.567
Smoot, Rory L. ; Koch, Cody A. ; Degnim, Amy C ; Sterioff, Sylvester ; Donohue, John H. ; Grant, Clive S. ; Barnes, Sunni A. ; Gullerud, Rachel E. ; Hobday, Timothy James ; Farley, David R. / A single-center experience with inflammatory breast cancer, 1985-2003. In: Archives of Surgery. 2006 ; Vol. 141, No. 6. pp. 567-572.
@article{8d853757553e42abb66498190086f385,
title = "A single-center experience with inflammatory breast cancer, 1985-2003",
abstract = "Hypothesis: {"}Up-front{"} surgery improves survival in inflammatory breast cancer (IBC). Design: Retrospective cohort, 1985-2003. Setting: Tertiary referral center. Patients: Consecutive patients with a primary occurrence of IBC. Main Outcome Measures: All-cause and disease-free survival. Results: One-hundred fifty-six patients were identified with IBC; 28 patients with metastatic disease were excluded from further analysis. The mean age of the remaining 128 patients was 53 years; 57{\%} of women were postmenopausal. One hundred twenty-two patients had clinically apparent IBC. Tumors were palpable in 83 patients (mean diameter, 9.1 cm). Neoadjuvant chemotherapy was the initial therapy in 106 patients, while surgery was the initial therapy in 22 patients. The overall median survival was 37 months, with a median disease-free interval of 23 months. The 5-year survival was 42{\%}, with a disease-free survival of 21{\%}. Univariate analysis of recurrence identified previous hormone therapy (relative risk [RR], 0.50; P=.03), menopause (RR, 0.55; P=.01), and palpable adenopathy (RR, 1.57; P=.04) as significant factors. Univariate survival analysis highlighted previous hormone therapy (RR, 0.48; P=.04), radiotherapy (RR, 0.39; P=.02), sequence of therapy (P=.001), family history (RR, 0.47; P=.01), and palpable adenopathy (RR, 2.22; P<.001) as being important. Multivariate analysis of recurrence identified menopausal status as the key factor. Adenopathy at the initial examination was associated with decreased length of survival, while radiotherapy was associated with better survival. Conclusions: Survival from IBC remains poor. Although adenopathy and radiotherapy affected survival by multivariate analysis, the sequence of therapy was not associated with improved outcome.",
author = "Smoot, {Rory L.} and Koch, {Cody A.} and Degnim, {Amy C} and Sylvester Sterioff and Donohue, {John H.} and Grant, {Clive S.} and Barnes, {Sunni A.} and Gullerud, {Rachel E.} and Hobday, {Timothy James} and Farley, {David R.}",
year = "2006",
doi = "10.1001/archsurg.141.6.567",
language = "English (US)",
volume = "141",
pages = "567--572",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - A single-center experience with inflammatory breast cancer, 1985-2003

AU - Smoot, Rory L.

AU - Koch, Cody A.

AU - Degnim, Amy C

AU - Sterioff, Sylvester

AU - Donohue, John H.

AU - Grant, Clive S.

AU - Barnes, Sunni A.

AU - Gullerud, Rachel E.

AU - Hobday, Timothy James

AU - Farley, David R.

PY - 2006

Y1 - 2006

N2 - Hypothesis: "Up-front" surgery improves survival in inflammatory breast cancer (IBC). Design: Retrospective cohort, 1985-2003. Setting: Tertiary referral center. Patients: Consecutive patients with a primary occurrence of IBC. Main Outcome Measures: All-cause and disease-free survival. Results: One-hundred fifty-six patients were identified with IBC; 28 patients with metastatic disease were excluded from further analysis. The mean age of the remaining 128 patients was 53 years; 57% of women were postmenopausal. One hundred twenty-two patients had clinically apparent IBC. Tumors were palpable in 83 patients (mean diameter, 9.1 cm). Neoadjuvant chemotherapy was the initial therapy in 106 patients, while surgery was the initial therapy in 22 patients. The overall median survival was 37 months, with a median disease-free interval of 23 months. The 5-year survival was 42%, with a disease-free survival of 21%. Univariate analysis of recurrence identified previous hormone therapy (relative risk [RR], 0.50; P=.03), menopause (RR, 0.55; P=.01), and palpable adenopathy (RR, 1.57; P=.04) as significant factors. Univariate survival analysis highlighted previous hormone therapy (RR, 0.48; P=.04), radiotherapy (RR, 0.39; P=.02), sequence of therapy (P=.001), family history (RR, 0.47; P=.01), and palpable adenopathy (RR, 2.22; P<.001) as being important. Multivariate analysis of recurrence identified menopausal status as the key factor. Adenopathy at the initial examination was associated with decreased length of survival, while radiotherapy was associated with better survival. Conclusions: Survival from IBC remains poor. Although adenopathy and radiotherapy affected survival by multivariate analysis, the sequence of therapy was not associated with improved outcome.

AB - Hypothesis: "Up-front" surgery improves survival in inflammatory breast cancer (IBC). Design: Retrospective cohort, 1985-2003. Setting: Tertiary referral center. Patients: Consecutive patients with a primary occurrence of IBC. Main Outcome Measures: All-cause and disease-free survival. Results: One-hundred fifty-six patients were identified with IBC; 28 patients with metastatic disease were excluded from further analysis. The mean age of the remaining 128 patients was 53 years; 57% of women were postmenopausal. One hundred twenty-two patients had clinically apparent IBC. Tumors were palpable in 83 patients (mean diameter, 9.1 cm). Neoadjuvant chemotherapy was the initial therapy in 106 patients, while surgery was the initial therapy in 22 patients. The overall median survival was 37 months, with a median disease-free interval of 23 months. The 5-year survival was 42%, with a disease-free survival of 21%. Univariate analysis of recurrence identified previous hormone therapy (relative risk [RR], 0.50; P=.03), menopause (RR, 0.55; P=.01), and palpable adenopathy (RR, 1.57; P=.04) as significant factors. Univariate survival analysis highlighted previous hormone therapy (RR, 0.48; P=.04), radiotherapy (RR, 0.39; P=.02), sequence of therapy (P=.001), family history (RR, 0.47; P=.01), and palpable adenopathy (RR, 2.22; P<.001) as being important. Multivariate analysis of recurrence identified menopausal status as the key factor. Adenopathy at the initial examination was associated with decreased length of survival, while radiotherapy was associated with better survival. Conclusions: Survival from IBC remains poor. Although adenopathy and radiotherapy affected survival by multivariate analysis, the sequence of therapy was not associated with improved outcome.

UR - http://www.scopus.com/inward/record.url?scp=33745267735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745267735&partnerID=8YFLogxK

U2 - 10.1001/archsurg.141.6.567

DO - 10.1001/archsurg.141.6.567

M3 - Article

C2 - 16785357

AN - SCOPUS:33745267735

VL - 141

SP - 567

EP - 572

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 6

ER -